Growth marketing for GLP-1 & weight-loss brands
Compliant paid acquisition for compounded and brand-name GLP-1 programs - engineered for the one economics that actually matters here: retention-adjusted payback, not vanity ROAS.
Market context
Roughly 10 million Americans are on branded GLP-1s in 2026 (up from 6M in 2024), with J.P. Morgan projecting 30M US patients and a $200B global incretin market by 2030. The 2026 land-grab: the FDA declared the shortages resolved (removing legal cover for mass-market compounding), and Lilly (LillyDirect) and Novo (NovoCare) launched cash-pay programs - Zepbound $299–$449/mo, Wegovy $199–$349/mo - collapsing the price umbrella compounders lived under. Distribution, trust, and CAC efficiency now decide winners.
The glp-1 & weight loss growth playbook
Demand is red-hot, but ad accounts get disabled overnight and retention - not CAC - decides whether the model survives.
Advertise the program, not the molecule
Meta drives the bulk of scaled DTC weight-loss acquisition, but its Health & Wellness policy bans before/after imagery, negative self-perception framing, and marketing compounded GLP-1s as equivalent to branded drugs - and 35+ state AGs pressured Meta in late 2025 to purge misleading ads. Google captures high-intent branded demand but needs LegitScript/pharmacy certification for Rx terms. Use TikTok for cheap top-of-funnel education, then retarget on Meta/Google.
Creative: specific, credible, native
Buyer sophistication has spiked - generic "lose weight fast" no longer converts. What works: relatable UGC testimonials with compliant disclaimers, "do you qualify?" eligibility hooks, and cost/access reframes ("brand-name Wegovy from $199/mo"). Segment hard (a 45-year-old woman researching Rx needs a different ad than a 32-year-old man) and ship 3+ hook variants per concept - the hook carries ~70% of performance.
The quiz → async-Rx → subscription machine
A 2–3 minute eligibility quiz (BMI ≥30, or ≥27 with a comorbidity) qualifies and segments the lead, feeding an asynchronous clinical intake that turns a script within 24–48 hours. Default users into a monthly subscription, not one-off fills, and use the cash-pay reframe as the offer wedge. The quiz doubles as your CRM entry point, so instrument SMS/email abandonment recovery.
Retention is the whole game
50–65% of non-diabetic GLP-1 patients discontinue within 12 months, with GI distress driving ~62% of drop-offs and the steepest churn in the first 3 months - before meaningful weight loss lands. The LTV lever is proactive side-effect coaching, slower titration, anti-nausea support, and plateau/maintenance education - not more ad spend.
Compliance landmines
Common mistakes in glp-1 & weight loss
- Running before/after or side-by-side transformation creative on Meta - an automatic policy rejection and account-risk trigger.
- Marketing compounded GLP-1 as equivalent to branded Wegovy/Zepbound, or leaning on compounding as if the shortage exemption still exists.
- Skipping LegitScript/pharmacy certification and getting Rx ad accounts suspended before you scale.
- Optimizing to first-fill CAC while ignoring month-1 GI-distress churn - you buy patients who quit before margin turns positive.
- Using fear/shame framing or AI-generated fake testimonials - now an active state-AG enforcement target.
What good looks like
- Blended CAC $250–$500 per paying patient
- Quiz completion rate 45–60%+ from ad click
- Consult-to-Rx (qualified intake → prescription) 60–75%
- 90-day retention above 65–70%; LTV:CAC ≥ 3:1, payback under ~6–12 months
Segments we work in
What we do for glp-1 & weight loss brands
GLP-1 & weight loss marketing FAQ
Ready to lower CAC on your glp-1 & weight loss brand?
A 30-minute call with a senior strategist. Free account audit included. No pitch deck - a written plan you can keep, whether you work with us or not.
Book a free strategy call